BANZEL helps
a broad range of seizure types
BANZEL was studied across 10 different seizure types associated with LGS.1
LEARN MORE ABOUT DIFFERENT SEIZURE TYPESBANZEL helps
reduce severity and frequency of seizures
In a clinical trial of 138 people with LGS (ages 4-30) where BANZEL was added to their current therapy,2 BANZEL:
Reduced the severity
of seizures by
53.4%*
Reduced frequency of
tonic-atonic seizures by
42.5%†
Reduced frequency
of total seizures by
32.7%‡
BANZEL for adults with LGS
The full clinical trial results were based on all of the people in the trial (including both children and adults). The clinical trial was not specifically designed to study efficacy in adults only. Actual results may vary.
The following results were based only on the adults in the trial. In the clinical trial with 138 patients, 21 adults (18 years and older) received BANZEL and 10 received placebo. These adults saw the following results3:
Reduced total
seizures by
31.5%§
Reduced tonic-atonic
seizures by
54.9%||
What to remember about treatment with BANZEL
Understand possible side effects
BANZEL is an add-on medication that can cause side effects and affect how other seizure medications work. Other medicines should not be started or stopped without talking to your doctor. Be sure to talk with your doctor for more information about the risks associated with BANZEL
References:
- Eisai Data on File. Study No. CRUF331 0022. Release date January 26, 2005.
- BANZEL Prescribing Information.
- McMurray M. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016;5:35–43.